RED1,2,3: NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia.
RED1,2,3: NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. (Decision date - September 2017)
RED1,2,3: NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma. (Decision date - April 2018)
RED1,2,3: NICE TA629: Obinutuzumab with bendamustine followed by obinutuzumab maintenance for treating follicular lymphoma that did not respond or progressed up to 6 months after treatment with rituximab (Decision date - June 2020)
RED: SSC2579: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults) as per NHSE commissioning intentions (Decision - December 2023)